Maintaining Ischemic Protection While Improving Safety Outcomes: Can We Standardize Short Infusion Glycoprotein IIb/IIIa Inhibitor Use? - Michael Lipinski

↳ This is a section part of Moment: CRT 2017 : Optimization of Anticoagulation for STEMI Therapy - Supported by educational grants from AstraZenca, Chiesi USA, Inc. and Medicure, Inc.

Add this Moment to your Passport

Learn from this moment and keep it forever.

Add To Passport

$16.99

This moment is included in Simple Premium - Get started for free.

FREE with Simple Premium

Start your 30-day free trial

Simple Premium offers unlimited access to all premium moments. $30.00 per month. Cancel anytime.

Preview

Summary

Maintaining Ischemic Protection While Improving Safety Outcomes: Can We Standardize Short Infusion Glycoprotein IIb/IIIa Inhibitor Use? - Michael Lipinski at CRT 2017.

Add this Moment to your Passport

Learn from this moment and keep it forever.

Add To Passport

$16.99

This moment is included in Simple Premium - Get started for free.

FREE with Simple Premium

Start your 30-day free trial

Simple Premium offers unlimited access to all premium moments. $30.00 per month. Cancel anytime.

Target Audience

Learning Objectives

Other Components in this Moment

Overview

Case Presentation - Kyle Buchanan

Is There Such a Thing as Adequate P2Y12 Pretreatment for ACS?: Contemporary Use of IV Antiplatelet Agents - Paul Gurbel

Maintaining Ischemic Protection While Improving Safety Outcomes: Can We Standardize Short Infusion Glycoprotein IIb/IIIa Inhibitor Use? - Michael Lipinski

Antiplatelet Options in the Cathlab: How Can We Find Value? - Michael Lipinski

Case Presentation - M Chadi Alraies

Should We Preload STEMI Patients With Antiplatelet Therapy? - A. Michael Lincoff

Antiplatelet Therapy for STEMI: The Case for Cangrelor - Gary Schaer

The Role of Long-Term DAPT after STEMI - David Cohen